# US 2011/0257029 A1 · Biomarkers for pancreatic cancer and diagnostic methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257029 A1
- Document ID: US20110257029A1
- Status: Published application
- Kind: A1
- Application number: 12/951,718
- Filed: 2010-11-22
- Published: 2011-10-20
- Earliest claimed: 2005-04-15
- Assignees: Van Andel Research Institute; University of Pittsburgh—Of the Commonwealth System of Higher Education
- Inventors: Brian B. Haab; Tingting Yue; Randall E. Brand
- Web page: https://patentgrep.com/patent/US20110257029A1

## CPC

- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 33/57525: of the liver or pancreas
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease.

## Claims

### Claim 1

A method for differentiating pancreatic cancer from a benign pancreatic disease, comprising the steps:
obtaining a patient biological sample from a patient having or suspected of having a pancreatic disease;
assaying the patient biological sample (a) for a total level of CA 19-9 antigen in the patient biological sample and (b) for a glycan level in MUC16 in the patient biological sample;
comparing the total level of CA 19-9 antigen in the patient biological sample to a statistically validated threshold for total CA 19-9 antigen, which statistically validated threshold for total CA 19-9 antigen is based on a total level of CA 19-9 antigen in comparable control biological samples from patients having a benign pancreatic disease; and
comparing the glycan level in the MUC16 in the patient biological sample to a statistically validated threshold for the MUC16, which statistically validated threshold for the MUC16 is based on a glycan level in the MUC16 in comparable control biological samples from patients having a benign pancreatic disease;
wherein (a) a different level of total CA 19-9 antigen in the patient biological sample as compared to the statistically validated threshold for total CA 19-9 antigen and (b) a different level of glycan level in the MUC16 in the patient biological sample as compared to the statistically validated threshold for the MUC16 indicate that the patient has pancreatic cancer rather than a benign pancreatic disease.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein pancreatitis is the benign pancreatic disease.

### Claim 4 (depends on 1)

The method of claim 1, further comprising the step of diagnosing pancreatic cancer in the patient.

### Claim 5 (depends on 1)

The method of claim 1, further comprising reporting the indication of pancreatic cancer to the patient or a physician.

### Claim 6 (depends on 1)

The method of claim 1, further comprising providing a treatment for pancreatic cancer to the patient.

### Claim 7 (depends on 1)

The method of claim 1, further comprising providing a monoclonal antibody to the CA-19-9 antigen and using the monoclonal antibody in assaying for (a) the total CA 19-9 antigen in the patient biological sample and (b) the glycan level in the MUC16 in the patient biological sample.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, further comprising the steps:
assaying the patient biological sample for a glycan level in MUC5AC in the patient biological sample;
comparing the glycan level in the MUC5AC in the patient biological sample to a statistically validated threshold for the MUC5AC, which statistically validated threshold for the MUC5AC is based on a glycan level in the MUC5AC in comparable control biological samples from patients having a benign pancreatic disease;
wherein (a) a different level of total CA 19-9 antigen in the patient biological sample as compared to the statistically validated threshold for total CA 19-9 antigen, (b) a different level of glycan level in the MUC16 in the patient biological sample as compared to the statistically validated threshold for the MUC16, and (c) a different level of glycan level in the MUC5AC in the patient biological sample as compared to the statistically validated threshold for the MUC5AC indicate that the patient has pancreatic cancer rather than a benign pancreatic disease.

### Claim 10 (depends on 9)

The method of claim 9, further comprising assaying MUC16 with a glycan binding protein other than the monoclonal antibody to the CA 19-9 antigen.

### Claim 11 (depends on 10)

The method of claim 10, wherein the glycan binding protein other than the monoclonal antibody to the CA 19-9 antigen is Bauhinea Purpurea lectin (BPL).

### Claim 12 (depends on 9)

The method of claim 9, further comprising the steps of:
assaying the patient biological sample for a glycan level in MUC1 in the patient biological sample;
comparing the glycan level in the MUC1 in the patient biological sample to a statistically validated threshold for the MUC1, which statistically validated threshold for the MUC1 is based on a glycan level in the MUC1 in comparable control biological samples from patients having a benign pancreatic disease;
wherein (a) a different level of total CA 19-9 antigen in the patient biological sample as compared to the statistically validated threshold for total CA 19-9 antigen, (b) a different level of glycan level in the MUC16 in the patient biological sample as compared to the statistically validated threshold for the MUC16, (c) a different level of glycan level in the MUC5AC in the patient biological sample as compared to the statistically validated threshold for the MUC5AC, and (d) a different level of glycan level in the MUC1 in the patient biological sample as compared to the statistically validated threshold for the MUC1 indicate that the patient has pancreatic cancer rather than a benign pancreatic disease.

### Claim 13 (depends on 12)

The method of claim 12, further comprising assaying MUC16 with a glycan binding protein other than the monoclonal antibody to the CA 19-9 antigen.

### Claim 14 (depends on 13)

The method of claim 13, wherein the glycan binding protein other than the monoclonal antibody to the CA 19-9 antigen is BPL.

### Claim 15 (depends on 1)

The method of claim 1, wherein the patient biological sample is plasma or serum from the patient.

### Claim 16

A kit for differentiating pancreatic cancer from a benign pancreatic disease comprising:
an antibody array having (a) a CA 19-9 capture antibody bound thereto and (b) an anti-MUC16 capture antibody bound thereto;
a detection monoclonal antibody to the CA-19-9 antigen; and
a container for the detection monoclonal antibody to the CA-19-9 antigen.

### Claim 17 (depends on 16)

The kit of claim 16, further comprising a glycan binding protein other than the detection monoclonal antibody to the CA 19-9 antigen and
a container for the glycan binding protein other than the detection monoclonal antibody to the CA 19-9 antigen.

### Claim 18 (depends on 16)

The kit of claim 16, wherein the antibody array further comprises an anti-MUC5AC capture antibody bound thereto.

### Claim 19 (depends on 18)

The kit of claim 18, wherein the antibody array further comprises an anti-MUC1 capture antibody bound thereto.

### Claim 20

(canceled)

### Claim 21 (depends on 17)

The kit of claim 17, wherein the glycan binding protein other than the detection monoclonal antibody to the CA 19-9 antigen is selected from the group consisting of Aleuria Aurantia lectin (AAL), Wheat Germ Agglutinin (WGA), Jacalin, Bauhinea Purpurea lectin (BPL), Sambucus Nigra lectin (SNA), and a glycan-binding antibody.

### Claim 22 (depends on 21)

The kit of claim 21, wherein the glycan binding protein other than the detection monoclonal antibody to the CA 19-9 antigen is BPL.

### Claim 23 (depends on 16)

The kit of claim 16 wherein the benign pancreatic disease is pancreatitis.

### Claim 24

A method for differentiating pancreatic cancer from a benign pancreatic disease, comprising the steps:
obtaining a serum or plasma sample from a patient having or suspected of having a pancreatic disease;
assaying the sample for a total level of CA 19-9 antigen in the sample;
assaying the sample for a glycan level in one or more mucins in the sample;
determining whether there is a different total level of CA 19-9 antigen in the sample as compared to a statistically validated threshold for total CA 19-9 antigen, which statistically validated threshold for total CA 19-9 antigen is based on a total level of CA 19-9 antigen in comparable control serum or plasma samples from patients having a benign pancreatic disease;
determining whether there is a different glycan level in the one or more mucins in the sample as compared to a statistically validated threshold for the glycan level in the one or more mucins, which statistically validated threshold for the glycan level in the one or more mucins is based on the glycan level in the one or more mucins in comparable control serum or plasma samples from patients having a benign pancreatic disease; and
diagnosing pancreatic cancer or a benign pancreatic disease in the patient.

### Claim 25 (depends on 24)

The method of claim 24, wherein the one or more mucins is selected from the group consisting of MUC1, MUC5AC, and MUC16.

### Claim 26 (depends on 24)

The method of claim 24, wherein pancreatitis is the benign pancreatic disease.

### Claim 27 (depends on 24)

The method of claim 24, further comprising providing a monoclonal antibody to the CA-19-9 antigen and using the monoclonal antibody in assaying for (a) the total CA 19-9 antigen in the patient biological sample and (b) the glycan level in the one or more mucins in the sample.

### Claim 28 (depends on 24)

The method of claim 24, wherein the one or more mucins in the sample that is assayed is MUC16.

### Claim 29 (depends on 28)

The method of claim 28, wherein the one or more mucins in the sample are MUC16 and MUC5AC.

### Claim 30 (depends on 29)

The method of claim 29, further comprising assaying MUC16 with a glycan binding protein other than the monoclonal antibody to the CA 19-9 antigen.

### Claim 31 (depends on 30)

The method of claim 30, wherein the glycan binding protein other than the monoclonal antibody to the CA 19-9 antigen is Bauhinea Purpurea lectin (BPL).

### Claim 32 (depends on 29)

The method of claim 29, wherein the mucins in the sample that are assayed are MUC16, MUC5AC, and MUC1.

### Claim 33 (depends on 32)

The method of claim 32, further comprising assaying MUC16 with a glycan binding protein other than the monoclonal antibody to the CA 19-9 antigen.

### Claim 34 (depends on 33)

The method of claim 33, wherein the glycan binding protein other than the monoclonal antibody to the CA 19-9 antigen is BPL.
